Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Equity Average (2020 - 2026)

GeneDx Holdings has reported Equity Average over the past 7 years, most recently at $281.2 million for Q1 2026.

  • Quarterly Equity Average rose 11.87% to $281.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $281.2 million through Mar 2026, up 11.87% year-over-year, with the annual reading at $276.7 million for FY2025, 16.94% up from the prior year.
  • Equity Average was $281.2 million for Q1 2026 at GeneDx Holdings, down from $300.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $599.3 million in Q3 2022 and troughed at $199.3 million in Q3 2024.
  • The 5-year median for Equity Average is $281.2 million (2026), against an average of $305.6 million.
  • Year-over-year, Equity Average soared 783.01% in 2022 and then tumbled 54.08% in 2023.
  • A 5-year view of Equity Average shows it stood at $407.5 million in 2022, then crashed by 40.83% to $241.1 million in 2023, then decreased by 6.74% to $224.9 million in 2024, then soared by 33.51% to $300.2 million in 2025, then fell by 6.35% to $281.2 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Equity Average are $281.2 million (Q1 2026), $300.2 million (Q4 2025), and $284.7 million (Q3 2025).